News

For a $950 million upfront, Sobi is all set to get rights to pozdeutinurad - oral URAT1 inhibitor that performed pretty well in the Phase II studies. Sobi is taking over Arthrosi Therapeutics, which is California-based, in a move to...

Bicycle Therapeutics has entered into a 15-year agreement with the UK Nuclear Decommissioning Authority (NDA) to utilize reprocessed uranium from nuclear reactors for the production of precision cancer therapies. Under the terms of the deal, announced by the UK government,...

On December 12, 2025, the U.S. health regulator went ahead and approved the oral antibiotic by Innoviva for treatment of gonorrhea, which is a common sexually transmitted infection, by way of offering patients an alternative to the injectable drug,...

In one of the most prominent developments for the biotech sector, BaseLaunch has officially welcomed Takeda as its new pharmaceutical partner. This collaboration is going to enhance the present partnership with five other leading pharma companies, now totaling six....

Pfizer has confirmed that it has struck an almost $2.1bn licensing deal with YaoPharma in order to develop as well as commercialize its obesity pill, hence furthering its push into the weight loss spectrum. It is worth noting that the...

Liquid biopsy has become the quiet revolution of early cancer detection. It helps analyze circulating tumor DNA or tumor cells directly from blood. But behind the buzz lies a reality every scientist knows: for early-stage disease, detecting circulating tumor...

The European Commission has stepped up and given the nod to €47 million in German state aid for Vetter Pharma, which is a German pharmaceutical service provider. The aid is going to support the establishment when it comes to a new aseptic filling...